Business Model & Revenue
Agenus Inc. (NASDAQ: AGEN) is an immuno-oncology company with revenue from Shingrix vaccine adjuvant royalties and antibody discovery partnerships. Pipeline: botensilimab (anti-CTLA-4) + balstilimab (anti-PD-1) for solid tumors. Lexington, MA. TTM Revenue: $123.87M, Gross Margin: 99.5%.
Financial Highlights
| Metric | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | $123.87M | $114.21M | $103.46M | $156.31M |
| Gross Profit | $123.22M | $113.17M | $102.98M | $153.20M |
| Gross Margin | 99.5% | 99.1% | 99.5% | 98.1% |
| SG&A | $45.53M | $54.39M | $71.88M | $78.74M |
| R&D | $69.64M | $79.34M | $155M+ | — |
| Private Placement | $85M + $255M warrants | — | — | — |
Revenue from royalties is near-100% margin. The $85M placement + potential $255M warrants = up to $340M capital.
Competitive Landscape
Checkpoint inhibitors: Merck (Keytruda/pembrolizumab, anti-PD-1), BMS (Opdivo/nivolumab, anti-PD-1 + Yervoy/ipilimumab, anti-CTLA-4). Agenus's botensilimab/balstilimab targets the same space but with a differentiated Fc-engineered CTLA-4 antibody.
Catalysts
-
ASCO 2026 data presentation: Noetik TARIO-2 tumor microenvironment analysis for botensilimab/balstilimab.
-
Phase 3 initiation: If the combo moves into pivotal trials in MSS colorectal cancer or ovarian cancer.
-
Warrant exercises: If the $255M in warrants are exercised, it validates institutional confidence.
-
Additional partnership deals: Agenus's antibody discovery platform could generate new partnerships.
-
FDA breakthrough designation: If botensilimab/balstilimab receives BTD based on emerging data.
Key Risks
- ($88M) operating loss annually. Even with $124M revenue, OpEx exceeds income.
- Botensilimab/balstilimab needs Phase 3 confirmation. Checkpoint inhibitor market is competitive.
- Private placement is dilutive — $255M in warrants if exercised.
- Revenue largely dependent on Shingrix royalties — if GSK modifies the agreement, revenue drops.
- AI-driven retrospective data is promising but not prospective clinical validation.
Our Thesis
Agenus has a rare advantage among micro cap biotechs: $124M in royalty and partnership revenue. The Shingrix adjuvant royalty stream provides predictable, high-margin revenue that funds pipeline development without burning cash on overhead alone. This is a biotech with a revenue foundation.
The botensilimab/balstilimab combo is a differentiated approach to checkpoint inhibition. The new AI-driven data from Noetik's TARIO-2 model adds a precision medicine angle — identifying which patients benefit most. If the retrospective data translates to prospective clinical outcomes, the combo could compete with established checkpoints (Keytruda, Opdivo) in specific tumor types.
The $85M placement at a premium to pre-surge levels signals institutional confidence. $340M total potential capital (including warrants) would fund years of clinical development.
Risks: Phase 3 data is needed. The CTLA-4/PD-1 space is competitive. Operating losses of $88M+ will burn through the placement.
Speculative Buy. Real revenue, funded pipeline, and data catalysts create asymmetric upside.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.